



Comprehensive laboratory testing for the
screening, prevention, and management of HIV

Diagnostic solutions to help drive better outcomes



~32K

new HIV infections diagnosed in 2022¹



70%

estimated new HIV infections in 2022 among Black and Hispanic Americans¹



1.2M

people are living with HIV in the US¹

HIV screening is **important in early diagnosis and treatment and in reducing the risk of transmission.**

Comprehensive testing menu to support every step in the care continuum



SCREEN



CARE



PREVENT

Combination antigen and antibody testing for earliest identification of HIV infection

- Identifying HIV early to maximize treatment options
- The Centers for Disease Control (CDC) recommends screening all patients ages 13-65 for HIV at least once, regardless of their risk level, using an opt-out approach¹

Comprehensive test offerings to support ongoing HIV management

- Immune status and viral load monitoring
- Antiretroviral therapy (ART) selection, drug resistance, and tropism
- Identify coinfections with other blood-borne pathogens (eg, HBV, HCV)


CDC guideline-recommended PrEP testing


- Flexible testing menu tailored to patients' unique needs
- Billing and reimbursement challenges mitigated by test naming and coding

Diagnostic screening for **every adult patient**

The appropriate testing can help prevent transmission and improve outcomes

The CDC and HIV.gov recommend the following screenings for HIV

 **One-time testing is recommended** for all individuals ages 13–65²

 People engaging in risky behaviors **should get tested at least once every year**³

Screening everyone helps patients

- ✓ Make informed decisions
- ✓ Combat spread of the disease
- ✓ Seek treatment sooner
- ✓ Take advantage of preventive measures that help limit the transmission of infection

Quest offers a comprehensive set of HIV screening and diagnostic tools for every adult in your practice so you can help your patients make confident, informed decisions wherever they are in the care continuum, from routine screening to treatment monitoring.

Every adult can benefit from following CDC guidelines for HIV screening and monitoring⁵

HIV screening options

Test code	Test name	Use case
91431	HIV-1/2 Antigen and Antibodies, Fourth Generation, with Reflexes	Helps diagnose HIV-1 and HIV-2 infection, including acute infection, and differentiate HIV-1 from HIV-2
16185	HIV-1 RNA, Qualitative, Real-Time PCR	Detects HIV-1 RNA in human serum and plasma by PCR as an aid in diagnosis of HIV-1 infection
8401	HIV-1 DNA, Qualitative, PCR	For use in conjunction with clinical presentation and other laboratory markers of disease progress in the clinical management of patients infected with HIV-1



SCREEN



CDC recommends
4th generation antigen/antibody assays for detection, diagnosis⁴



Caring for the **HIV patient**

Quest provides the full array of testing to guide every step of the care continuum

Determining immune status and viral load⁶

CD4+ T-cell count is the most valuable indicator of immune status and predictor of disease progression and survival in HIV+ patients. CD4 counts should be measured at diagnosis and monitored every 3-6 months in patients who do not immediately start antiretroviral therapy (ART).

HIV-1 viral load also helps determine risk of disease progression, informs treatment selection, and provides a baseline for assessing treatment response. Once ART is initiated, HIV viral load is an important indicator of therapeutic efficacy.

For those who have tested HIV-positive and completed 6 months or more of antiretroviral treatment, testing can help determine when their viral load reaches the point where there is no longer risk of transmission.



CARE



Achieve and maintain
an undetectable viral load and
prevent further transmission⁸

HIV—If someone is on effective treatment they can't pass it on.⁷

U = U
Undetectable Untransmittable

HIV care testing options^a

Test code	Test name	Use case
Immune status and viral load monitoring		
40085	HIV-1 RNA, Quantitative, Real-Time PCR	For the clinical management of HIV-1 infected patients as an aid in assessing patient prognosis and monitoring the effects of antiretroviral therapy
8360	Lymphocyte Subset Panel 5 <i>includes % CD4, absolute CD4+ cells, absolute lymphocytes</i>	For establishing baseline CD4 level, monitoring treatment progress, and to facilitate differential diagnoses between congenital and acquired immunodeficiency diseases
Selecting and adapting ART		
91691	HIV-1 RNA, Quantitative, Real-Time PCR with Reflex to Genotype (RTI, PI, Integrase)	For monitoring viral load in patients undergoing antiretroviral therapy and with automatic reflex to drug resistance testing in patients failing to achieve or maintain virologic suppression
94807	HIV-1 Resistance, Proviral DNA (RTI, PI, Integrase inhibitors)	For detecting drug-resistant mutations in virologically suppressed patients and assisting in modification of treatment regimens
91692	HIV-1, Genotype (RTI, PI, Integrase inhibitors)	For detecting drug-resistant-associated mutations to reverse transcriptase, protease, and integrase genes
34949	HIV-1 Genotype	For identifying drug-resistant mutations to predict antiretroviral drug resistance before initiation of therapy and managing patients experiencing virologic failure while on therapy
16868	HIV-1 Integrase Genotype	For detecting drug-resistant-associated mutations in integrase genes
94014	HIV-1 Coreceptor Tropism, Ultradeep Sequencing	For determining eligibility for treatment with CCR-5 antagonists
91299	HIV-1 Coreceptor Tropism, Proviral DNA	For determining eligibility for treatment with CCR-5 antagonists in virologically suppressed patients
19774	HLA-B*5701 Typing	Assess risk of abacavir hypersensitivity reaction

^a For Quest's full menu offering of HIV tests, please see online test directory.

Diagnostic testing solutions that support a pathway to pre-exposure prophylaxis (PrEP)

Our HIV PrEP test offerings include all the most recent CDC guideline-recommended tests to determine clinical eligibility and to monitor patients while on PrEP. Our flexible menu makes testing simple to meet your patient's needs.

The Quest PrEP testing difference:

- ✓ **Flexible testing options** so you can choose the right test based on your patient's unique requirements
- ✓ **Billing and reimbursement challenges** are mitigated by our updated menu offering
- ✓ **Gender-inclusive testing language** designed to cater to all your patients, regardless of gender
- ✓ **Accessible testing options** with approximately 2,000 patient service centers and in-office phlebotomists to help patients get the tests they need, when they need them



The CDC reports that PrEP can **reduce the risk of getting HIV from sex by about 99%** and from injection drug use by at least 74%⁹

Test code	Test name	Use case
13590	PrEP HIV-1/2 Antigen and Antibodies, Fourth Generation, Screen and HIV-1 RNA	For clinician determination of HIV status in patients with recent or ongoing antiretroviral prophylaxis use
13595	PrEP HIV-1/2 Antigen/Antibodies, 4th Generation, Reflex to Differentiation	For clinician determination of HIV status in patients without recent or ongoing antiretroviral prophylaxis use who are considering initiating PrEP
13600	PrEP HIV-1 RNA, Qualitative Real-Time PCR	For use as part of a multi-step algorithm for determination of HIV status in patients being considered for PrEP with likely HIV exposure but negative or indeterminate HIV antibody results
13670	PrEP HIV-1/2 Antigen and Antibodies, Fourth Generation, with Reflexes	For diagnosis of HIV-1 and HIV-2 infection, including acute infection, and to differentiate HIV-1 from HIV-2 in PrEP-naive patients
13660	PrEP HBV Triple Screen Panel with Reflexes includes HBV Surface Antigen with Reflex Confirmation; HBV Core Antibody, Total, with Reflex to IgM; HBV Surface Antibody, Quantitative	For screening for HBV in patients considering or who are currently taking HIV PrEP
13667	PrEP Hepatitis C Antibody with Reflex to HCV, RNA, Real-Time PCR	For screening for HBC in patients considering or who are currently taking HIV PrEP
13698	PrEP RPR (Diagnosis) with Reflex Titer and <i>Treponema pallidum</i> Antibody, IA	As part of a screening regimen for STIs in patients considering or who are currently taking HIV PrEP
13701	PrEP <i>Chlamydia/Neisseria gonorrhoeae</i> RNA, TMA, Urogenital	As part of a screening regimen for STIs in patients considering or who are currently taking HIV PrEP
13697	PrEP Creatinine	For evaluating kidney function in patients considering or currently taking HIV PrEP
13696	PrEP hCG, Total, Quantitative	As part of an overall screening regimen for patients considering or who are currently taking HIV PrEP
70051	<i>Chlamydia/Neisseria gonorrhoeae</i> RNA, TMA, Throat	As part of screening regimen for STIs that may infect the oral/pharyngeal cavity of sexually active individuals
16506	<i>Chlamydia/Neisseria gonorrhoeae</i> RNA, TMA, Rectal	As part of screening regimen for STIs that may infect the anal/rectal canal of sexually active individuals



3 out of 5 adults at risk for HIV are missing out on potentially lifesaving preventive treatments

The benefits of teaming with the largest provider of diagnostic testing insights and information services

- Guideline-based solutions driven by industry-leading expertise and investment
- Medical and scientific support from Quest's extensive team of MDs, PhDs, and other diagnostics experts
- Quantum® online lab services to simplify ordering with enhanced results, transparent pricing, and billing support on phone or laptop
- In-network access with most private insurance plans, Medicare, and Medicaid, which helps to minimize billing and reimbursement challenges
- Financial assistance programs where affordability is a barrier to appropriate care
- Convenient sample collection at almost 2,000 Quest patient service centers and in-office phlebotomists across the US



Learn more. Talk to your **Quest sales representative** or visit **QuestHIVTesting.com**



References

1. HIV.gov. US Statistics. Updated August 15, 2024. Accessed December 19, 2024. <https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics>
2. Clinical testing guidance for HIV. Updated September 10, 2024. Accessed November 15, 2024. <https://www.cdc.gov/hivnexus/hcp/diagnosis-testing/index.html>
3. HIV.gov. Who should get tested? Updated March 6, 2023. Accessed December 19, 2024. <https://www.hiv.gov/hiv-basics/hiv-testing/learn-about-hiv-testing/who-should-get-tested>
4. Branson BM, Owen SM, Wesolowski LG, et al. Laboratory testing for the diagnosis of HIV infection: updated recommendations. Centers for Disease Control and Prevention. June 27, 2014. Accessed February 22, 2022. doi:10.15620/cdc.23447
5. Etami Y, Zaheer MA, Marcus JL, Calabrese SK. Accuracy of HIV risk-related information and inclusion of undetectable=untransmittable, pre-exposure prophylaxis, and post-exposure prophylaxis on US Health Department websites. *AIDS Patient Care STDs*. 2023;37(9):425-427. doi:10.1089/apc.2023.0150
6. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Updated September 21, 2022. Accessed October 7, 2024. <https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf>
7. CDC. Undetectable = untransmittable. Updated August 19, 2024. Accessed November 19, 2024. <https://www.cdc.gov/global-hiv-tb/php/our-approach/undetectable-untransmittable.html>
8. CDC. Clinical care of HIV. Updated April 24, 2024. Accessed November 26, 2024. <https://www.cdc.gov/hivnexus/hcp/clinical-care/index.html>
9. National Institutes of Health. Pre-Exposure Prophylaxis (PrEP). Updated December 11, 2023. Accessed December 19, 2024. <https://hivinfo.nih.gov/understanding-hiv/fact-sheets/pre-exposure-prophylaxis-prep>

Test codes may vary by location. Please contact your local laboratory for more information.

Image content features models and is intended for illustrative purposes only.

QuestDiagnostics.com

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. SB6659 1/2025